Live

IlluminaIllumina stock (US4523271090): Corporate Responsibility Report highlights genomics growth drivers - AD HOC NEWS Eli LillyElil Lilly buys a Bay Area Y Combinator alum for up to $202M - The Business Journals PfizerPharma sector doubles down on AI amid hopes of slashing costs, timelines - Reuters FierceBiotechGHO Capital, CBC Group plan to merge, forming $21B healthcare investment firm Eli LillyEli Lilly Acquires Engage Bio | PharmExec - Pharmaceutical Executive Mettler ToledoMettler-Toledo stock (US5926881054): analysts’ targets and earnings keep focus on precision instru - AD HOC NEWS LabCorpLabcorp Launches AI-Powered App to Help Patients Understand Test Results - Clinical Lab Products RevvityRevvity Inc. stock (US76155R1086): investors weigh latest earnings and diagnostics focus - AD HOC NEWS Eli LillyCollaborative Drug Discovery Inks Deal with Eli Lilly to Accelerate Biotech Innovation - Genetic Engineering and Biotechnology News Clinical OMICsEarly Medical Care Linked to Rapid Gut Microbiome Shifts in Amazonian Indigenous Communities Clinical OMICsAI Shows Value for Breast Cancer Prediction Merck & Co.EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study - TradingView

BioWorld 20. Mai 2026

Roche reports new TREM2 agonists

F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful fo...

F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of rheumatoid arthritis, amyotrophic lateral sclerosis, frontotemporal dementia, multiple sclerosis, prion disease, stroke, Parkinson’s and Alzheimer’s disease.